Aclaris Therapeutics, Inc.
ACRS
$2.83
-$0.05-1.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -92.64% | -40.44% | 10.96% | -6,375.65% | 74.07% |
| Total Depreciation and Amortization | -38.55% | -52.89% | -47.33% | -37.28% | -18.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.19% | 47.05% | -21.56% | 571.26% | -50.26% |
| Change in Net Operating Assets | -97.61% | 116.21% | 78.51% | -107.49% | 909.45% |
| Cash from Operations | -149.69% | 18.90% | 37.27% | -32.20% | 189.59% |
| Capital Expenditure | -- | -250.00% | 68.15% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 395.64% | 836.63% | 12.93% | -1,210.29% | -91.43% |
| Cash from Investing | 394.81% | 848.81% | 13.58% | -1,275.14% | -91.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 9,042.86% | 113.33% |
| Repurchase of Common Stock | 100.00% | 18.18% | -400.00% | -- | 90.20% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -515.86% | -- |
| Cash from Financing | -13,936.36% | 18.18% | -400.00% | 152,104.08% | 125.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.59% | 61.91% | 243.35% | -2,854.30% | 214.54% |